Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to give clinicians critical insights to guide optimal treatment
PALO ALTO, Calif., May 27, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling capabilities of the Guardant Infinity™ smart liquid biopsy platform and its AI learning engine, which analyzes large sets of patient data to identify patterns and refine predictions.
Some of the groundbreaking new applications for the Guardant360 Liquid test will allow healthcare providers to do the following in order to improve patient outcomes:
Confirm no actionable mutations in lung and colorectal cancers—helping fast-track patients to treatment without extra testing.
Identify the origin of cancers when the primary site is unknown, guiding better diagnosis and therapy.
Classify breast ER/PR/HER2 status and lung cancer histology subtypes with high precision by interpreting tumor-specific methylation signatures, enhancing standard testing methods.
Use pharmacogenomics to identify genetic variations vital for safe and effective use of common anti-cancer therapies, including those with FDA black box labeling.
Detect human papillomavirus (HPV) and Epstein-Barr (EBV), which influence prognosis and treatment plans in certain cancers.
Determine Homologous Recombination Deficiency (HRD) status to inform use of specific therapies like PARP inhibitors and platinum-based chemotherapy.
Use Human Leukocyte Antigen (HLA) genotyping as a biomarker to inform therapy selection and identify clinical trial opportunities.
"For the first time ever, we're able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "This gives healthcare providers the insights they need about a patient's cancer to make smarter treatment decisions, even when they can't access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond."
Comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard of care in oncology and helps ensure that clinicians don't miss critical information about a patient's specific type of cancer. The Guardant360 Liquid test now provides access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers.
Guardant liquid biopsy tests have been clinically validated in more than 1,000 publications and research abstracts. Test results for Guardant360 Liquid are available within seven days. For more information, visit the Guardant Health website.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527809334/en/
Contacts
Investor Contact: Zarak Khurshidinvestors@guardanthealth.com
Media Contact: Michael Weistpress@guardanthealth.com +1 317-371-0035
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Over 64,000 pounds of butter recalled over allergen concerns
A voluntary recall has been issued for over 64,000 pounds of butter found to contain an undeclared allergen. The voluntary recall was initiated July 14 by food ingredient company Bunge North America, affecting 1,800 cases of its NH European Style Butter Blend which did not declare milk as an allergen on the label. As of July 30, the Food and Drug Administration (FDA) labeled it a Class II recall, the second-highest risk level. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. The butter was sent to 12 distribution centers located throughout the U.S., as well as a single distribution center located in the Dominican Republic. Affected cases were packaged in white paperboard and contained 36 blocks. Affected cases of butter contain the following identification information: Product code: 5023937 UPC: 1 00 78684 73961 2 Lot code: 5064036503 The butter recall is the latest in a string of food-and-drink-related issues across the U.S. Earlier this week, High Noon Hard Seltzers were recalled over a labeling error. Some cans, filled with High Noon Vodka Seltzer, were mislabeled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, drinking the beverage in these cans can result in unintentional alcohol consumption. However, no illnesses or adverse events have been reported to date. Two lots of the High Noon Beach Variety 12-packs were affected, according to a press release. High Noon initiated the recall after it discovered 'a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon,' according to the press release. The recalled High Noon Beach Variety 12-packs were sent to distributors in eight states who then shipped the product to retailers in six states — Florida, New York, Ohio, South Carolina, Virginia, and Wisconsin — between July 21 and 23. Even if they didn't purchase the High Noon packs, consumers are encouraged to ensure that their Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition, does not have the same lot codes as the recalled cans. Single-serve coffee pods have also been recalled this week. New Mexico Piñon Coffee announced in a press release that it was voluntarily recalling 154 boxes of its Dark Pinon Single Serve Cups, which have 10 pods per box. The recall was issued because of the 'potential introduction of food coloring into the cups,' which are compatible with Keurig machines, during brewing. The recalled coffee pods were sold at popular retailers nationwide, including Target, Costco, Walmart, and Kroger. Although there weren't any reports of illness or injury, consumers are urged to throw affected pods away or return them to the place of purchase.
Yahoo
8 minutes ago
- Yahoo
Grocery Outlet (GO) Q2 Earnings: What To Expect
Discount grocery store chain Grocery Outlet (NASDAQ:GO) will be reporting results this Tuesday after the bell. Here's what investors should know. Grocery Outlet met analysts' revenue expectations last quarter, reporting revenues of $1.13 billion, up 8.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Grocery Outlet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Grocery Outlet's revenue to grow 5.2% year on year to $1.19 billion, slowing from the 11.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Grocery Outlet has missed Wall Street's revenue estimates twice over the last two years. Looking at Grocery Outlet's peers in the non-discretionary retail segment, only Sprouts has reported results so far. It beat analysts' revenue estimates by 2.3%, delivering year-on-year sales growth of 17.3%. The stock was down 4.1% on the results. Read our full analysis of Sprouts's earnings results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the non-discretionary retail stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.1% on average over the last month. Grocery Outlet is up 4.2% during the same time and is heading into earnings with an average analyst price target of $15.62 (compared to the current share price of $13.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
8 minutes ago
- Yahoo
Flywire (FLYW) To Report Earnings Tomorrow: Here Is What To Expect
Cross border payment processor Flywire (NASDAQ: FLYW) will be announcing earnings results this Tuesday after the bell. Here's what to look for. Flywire beat analysts' revenue expectations by 5% last quarter, reporting revenues of $133.5 million, up 17% year on year. It was a strong quarter for the company, with a solid beat of analysts' EBITDA estimates. Is Flywire a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Flywire's revenue to grow 20.9% year on year to $125.4 million, slowing from the 22.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.07 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Flywire has missed Wall Street's revenue estimates three times over the last two years. Looking at Flywire's peers in the finance and hr software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Workiva delivered year-on-year revenue growth of 21.2%, beating analysts' expectations by 3%, and Asure reported revenues up 7.4%, falling short of estimates by 3.2%. Workiva traded up 32.2% following the results while Asure was down 13.6%. Read our full analysis of Workiva's results here and Asure's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the finance and hr software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5% on average over the last month. Flywire is down 11.3% during the same time and is heading into earnings with an average analyst price target of $13.45 (compared to the current share price of $10.57). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
